Education
About Us
Working with TipRanks
Follow Us
Abeona Therapeutics (ABEO)
NASDAQ:ABEO
ABEO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.93 - $7.54
Previous CloseN/A
Volume71.38K
Average Volume (3M)710.09K
Market Cap
$364.59M
Enterprise Value$176.74M
Total Cash (Recent Filing)$84.16M
Total Debt (Recent Filing)$23.98M
Price to Earnings (P/E)11.3
Beta1.03
Next Earnings
Nov 17, 2025EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.71
Shares Outstanding51,278,538
10 Day Avg. Volume916,114
30 Day Avg. Volume710,085
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.48
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-176.74
Enterprise Value/Ebitda-4.79
Forecast
1Y Price Target
$20.00Price Target Upside189.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAbeona announced the sale of its Rare Pediatric Disease Priority Review Voucher for gross proceeds of $155M, providing sufficient cash for more than two years of operating expenses.
Market LaunchZEVASKYN is now officially commercially available in the U.S. after the activation of Ann & Robert H. Lurie Children’s Hospital of Chicago as the first of five qualified treatment centers.
ReimbursementReimbursement pressure has been limited, with management noting 100% success on prior authorizations.
Bears Say
Market RisksRisks include slower than projected uptake for pz-cel in the United States upon market introduction and setbacks with earlier-stage pipeline programs.
PricingThe ZEVASKYN list price is $3.1M per treatment, with the potential to generate over $30M in total sales by the end of 2025 if 10-15 patients are treated.
Abeona Therapeutics News
ABEO FAQ
What was Abeona Therapeutics’s price range in the past 12 months?
Abeona Therapeutics lowest stock price was $3.93 and its highest was $7.54 in the past 12 months.
What is Abeona Therapeutics’s market cap?
Abeona Therapeutics’s market cap is $364.59M.
When is Abeona Therapeutics’s upcoming earnings report date?
Abeona Therapeutics’s upcoming earnings report date is Nov 17, 2025 which is in 81 days.
How were Abeona Therapeutics’s earnings last quarter?
Abeona Therapeutics released its earnings results on Aug 14, 2025. The company reported $1.71 earnings per share for the quarter, beating the consensus estimate of -$0.39 by $2.1.
Is Abeona Therapeutics overvalued?
According to Wall Street analysts Abeona Therapeutics’s price is currently Undervalued.
Does Abeona Therapeutics pay dividends?
Abeona Therapeutics does not currently pay dividends.
What is Abeona Therapeutics’s EPS estimate?
Abeona Therapeutics’s EPS estimate is -0.27.
How many shares outstanding does Abeona Therapeutics have?
Abeona Therapeutics has 51,278,538 shares outstanding.
What happened to Abeona Therapeutics’s price movement after its last earnings report?
Abeona Therapeutics reported an EPS of $1.71 in its last earnings report, beating expectations of -$0.39. Following the earnings report the stock price went up 10.213%.
Which hedge fund is a major shareholder of Abeona Therapeutics?
Currently, no hedge funds are holding shares in ABEO
Abeona Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.00 (189.86% Upside)
$20.00 (189.86% Upside)
Blogger Sentiment
Bullish
ABEO Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 189.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.86%
12-Months-Change
Fundamentals
Return on Equity
48.34%
Trailing 12-Months
Asset Growth
83.75%
Trailing 12-Months
Company Description
Abeona Therapeutics
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
ABEO Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call conveyed a generally positive sentiment with significant achievements like the FDA approval of ZEVASKYN and strong initial demand. Positive reimbursement trends and financial stability further support a positive outlook. However, logistical challenges in patient treatment and manufacturing scale-up present areas for improvement.View all ABEO earnings summariesABEO Stock 12 Month Forecast
Average Price Target
$20.00
▲(189.86% Upside)
Technical Analysis
Astria Therapeutics
―
iTeos Therapeutics
―
Atea Pharmaceuticals
―
Compass Therapeutics
―
Candel Therapeutics
―
Ownership Overview
5.79% Insiders
4.84% Mutual Funds
45.90% Other Institutional Investors
34.04% Public Companies and
Individual Investors